Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Raynaud

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
European Urology Oncology|August 29, 2024
Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal StatusYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Hormones & Cancer|October 8, 2018
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study ResultsYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Nature Communications|January 30, 2024
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationOlivier Kosmider, Céline Possémé, Marie Templé, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
European Urology Oncology|August 29, 2024
Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal StatusYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Hormones & Cancer|October 8, 2018
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study ResultsYann Neuzillet, Jean-Pierre Raynaud, Jean-François Dreyfus, et al.
Nature Communications|January 30, 2024
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationOlivier Kosmider, Céline Possémé, Marie Templé, et al.
Pageof 5